Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Other Current Liabilities: HK$62 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shenzhen Neptunus Interlong Bio-Technique Co Other Current Liabilities?

Shenzhen Neptunus Interlong Bio-Technique Co HKSE:08329 -1.00% Other Current Liabilities is HK$62 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Shenzhen Neptunus Interlong Bio-Technique Co's other current liabilities for the quarter that ended in Jun. 2026 was HK$62 Mil.

Shenzhen Neptunus Interlong Bio-Technique Co's quarterly other current liabilities increased from Jun. 2025 (HK$5 Mil) to Dec. 2025 (HK$34 Mil) and increased from Dec. 2025 (HK$34 Mil) to Jun. 2026 (HK$62 Mil).

Shenzhen Neptunus Interlong Bio-Technique Co's annual other current liabilities declined from Dec. 2023 (HK$39 Mil) to Dec. 2024 (HK$38 Mil) and declined from Dec. 2024 (HK$38 Mil) to Dec. 2025 (HK$34 Mil).

Shenzhen Neptunus Interlong Bio-Technique Co Other Current Liabilities Related Terms

Shenzhen Neptunus Interlong Bio-Technique Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Neptunus Interlong Bio-Technique Co Other Current Liabilities Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.71 32.21 39.37 38.49 34.49

Shenzhen Neptunus Interlong Bio-Technique Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.92 38.49 4.84 34.49 61.53

Shenzhen Neptunus Interlong Bio-Technique Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of HK$62 Mil mean?
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Other Current Liabilities of HK$62 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Other Current Liabilities too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Other Current Liabilities is HK$62 Mil.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Other Current Liabilities compare to ZTS?
Shenzhen Neptunus Interlong Bio-Technique Co's Other Current Liabilities of HK$62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co. Shenzhen Neptunus Interlong Bio-Technique Co's current Other Current Liabilities is HK$62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.10 — trading 23.8% below its estimated fair value. The current Other Current Liabilities is HK$62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Other Current Liabilities is HK$62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Address 979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.